Eli Lilly & Co. (LLY) Declares $0.5625 Quarterly Dividend; 2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly & Co. (LLY) Reports Election of Karen Walker to Board
October 16, 2018 6:45 AM EDTThe board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee.
Walker is the Senior Vice President and Chief Marketing Officer at Cisco where she has worked since 2009. Prior to joining... More
Lilly (LLY) Says New Data Showcasing its Growing Commitment in Rheumatology to be Featured at ACR/ARHP
October 15, 2018 6:47 AM EDTEli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Oct. 19-24, 2018, in Chicago.
Lilly will present 21 abstracts featuring new data for Taltz, including a late-breaking abstract and four oral presentations. Highlights include complete results from two Phase 3 studies, COAST-V and COAST-W, in adult patients with Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (rad-axSpA). Based on the positive results from the COAST-V... More
Goldman Sachs Reinstates Eli Lilly (LLY) at Neutral
October 15, 2018 4:52 AM EDTGoldman Sachs analyst Jamie Rubin reinstates coverage on Eli Lilly (NYSE: LLY) with a Neutral rating and a price target of $120.00.
The analyst returns to the name on the sidelines citing a fair valuation and potential for better upside opportunities elsewhere in the... More
